WHO Statement on Improving Availability and Transparency of Observational Studies on Influenza Vaccine Effectiveness
|
|
- Lambert Parrish
- 6 years ago
- Views:
Transcription
1 WHO Statement on Improving Availability and Transparency of Observational Studies on Influenza Vaccine Effectiveness Draft Version 9 June 2017 WHO vaccine policy recommendations are the result of rigorous scientific review. Careful evidence review is needed to evaluate and interpret the magnitude of vaccine effect, any variability due to geography or subpopulations vaccinated, any limitations due to study design and conduct, or other factors that are important for assessing the public health value of vaccination [1, 2]. Policy making requires expert interpretation of data, relying on both comprehensive data availability and transparency [1]. Thus, the underreporting or misreporting of biomedical research undermines the WHO policy making process [3-7]. WHO is actively engaged in multiple initiatives to promote research availability and transparency. In 2005, WHO called for the registration of all clinical trials [8], and in 2015 WHO issued a formal position that results from all clinical trials should be reported within 12 months of study completion [9, 10]. In a 2017 joint statement on public disclosure of results from clinical trials, several research funding agencies affirmed the WHO position that the prospective registration and timely public disclosure of results from all clinical trials are of critical scientific and ethical importance [11]. While the joint statement focused on clinical trials, it also stressed that issues of transparency, reduction of waste, and reporting bias are important for other types of research, including observational studies. The joint statement called for the development of transparency frameworks for these other types of research. Public health decision making regarding influenza vaccines is increasingly informed by observational studies. Influenza viruses are constantly mutating, necessitating annual reformulation of influenza vaccines and annual revaccination of individuals at risk. Vaccine performance can vary widely from year-to-year, depending on the degree of match between vaccine viruses and circulating viruses, age and comorbidities of the persons being vaccinated, and the specific vaccine product being used. Influenza vaccines are mainly used in high-income countries [12, 13], where placebo controlled trials are generally considered unethical due to recommendations for routine vaccine use, either in the entire population or in specific high-risk groups. Observational influenza vaccine effectiveness studies guide decisions regarding influenza vaccine strain composition [14], vaccine licensure [15], vaccine recommendations [16-18], and investment [19]. Thus, it is in the best interest of public health that influenza vaccine effectiveness data be comprehensively available and transparent to facilitate critical appraisal by decision makers. In February 2017, the WHO Immunization and Vaccine-related Implementation Research Advisory Committee (IVIR-AC) discussed the interpretation of influenza vaccine research for 1
2 the purposes of WHO policy decisions [20]. IVIR-AC noted the increasing reliance of WHO on observational influenza vaccine effectiveness studies and acknowledged a compelling need to insure the quality and comparability of such studies and to optimize their interpretation for policy making. It is in this context that WHO advises all individuals and groups conducting influenza vaccine effectiveness research to ensure data availability and transparency. The following should be done to facilitate this effort: Study registration and protocol availability Before a study is initiated, it should be registered in a publicly available, free-toaccess, searchable registry complying with WHO s international agreed standards. 1 Any changes to the study details or analysis plans should be updated. At the time of study registration, study protocols should be made publicly available on free-to-access, searchable websites or on existing data custodial websites [21] with the location noted in the registry. If these websites are not used, the results should be posted on a free-to-access, publicly available, searchable institutional website of the Regulatory Sponsor, Funder, or Principal Investigator. Reporting timeframes A manuscript including the main findings of studies should be submitted for publication in a peer reviewed biomedical journal within 12 months of study completion with an open access mechanism, unless there is a specific reason why open access cannot be used, or otherwise made available publicly at most within 24 months of study completion. Key results should be made publicly available within 12 months of study completion by posting to the results section of the study registry. 2 Where a registry is used without a results section available, the results should be posted on a free-to-access, publicly available, searchable institutional website of the Regulatory Sponsor, Funder or Principal Investigator. Registry identifier code/number in publication The registry identifier code/number should be included in all study publications and abstracts to facilitate linking of study-related publications and registry site records. 1 As of 9 June 2017, clinicaltrials.gov and ISRCTN allow registration of observational studies. 2 Key results refer to the Results items from the STROBE statement checklist and include descriptive data, outcome data, and main results. 2
3 Results reporting Reports should adhere to STROBE consensus guidance for observational research [22], when applicable. As with all observational studies, reports of observational influenza vaccine effectiveness studies should include sufficient details on the study participants, data collection, and analyses to enable readers to judge the validity of the study. Sharing of individual participants data The benefit of sharing research data and the facilitation of research through greater access to primary datasets is a principle which WHO sees as important. WHO is actively engaged with multiple initiatives related to data sharing, and WHO supports sharing of health research datasets whenever appropriate. WHO encourages researchers to deposit anonymized study datasets in a publicly available, free-toaccess, searchable website within 12 months of study completion unless there is a specific reason why this should not be done. 3
4 References 1. World Health Organization. Guidance for the Development of Evidence-Based Vaccination Related Recommendations. Available at: s.pdf. Accessed 10 March Duclos P, Durrheim DN, Reingold AL, Bhutta ZA, Vannice K, Rees H. Developing evidence-based immunization recommendations and GRADE. Vaccine 2012; 31(1): Miller JE, Korn D, Ross JS. Clinical trial registration, reporting, publication and FDAAA compliance: a cross-sectional analysis and ranking of new drugs approved by the FDA in BMJ open 2015; 5(11): e Saito H, Gill CJ. How frequently do the results from completed US clinical trials enter the public domain?--a statistical analysis of the ClinicalTrials.gov database. PloS one 2014; 9(7): e Manzoli L, Flacco ME, D'Addario M, et al. Non-publication and delayed publication of randomized trials on vaccines: survey. BMJ (Clinical research ed) 2014; 348: g Jones CW, Handler L, Crowell KE, Keil LG, Weaver MA, Platts-Mills TF. Nonpublication of large randomized clinical trials: cross sectional analysis. BMJ (Clinical research ed) 2013; 347: f Chen R, Desai NR, Ross JS, et al. Publication and reporting of clinical trial results: cross sectional analysis across academic medical centers. BMJ (Clinical research ed) 2016; 352: i World Health Organization. International Clinical Trials Registry Platform (ICTRP). 9. Moorthy VS, Karam G, Vannice KS, Kieny MP. Rationale for WHO's new position calling for prompt reporting and public disclosure of interventional clinical trial results. PLoS medicine 2015; 12(4): e World Health Organization. WHO Statement on Public Disclosure of Clinical Trial Results. Available at: Accessed 16 March Joint statement on public disclosure of results from clinical trials. Available at: Accessed 25 May Ortiz JR, Perut M, Dumolard L, et al. A global review of national influenza immunization policies: Analysis of the 2014 WHO/UNICEF Joint Reporting Form on immunization. Vaccine 2016; 34(45): Palache A, Oriol-Mathieu V, Fino M, Xydia-Charmanta M. Seasonal influenza vaccine dose distribution in 195 countries ( ): Little progress in estimated global vaccination coverage. Vaccine 2015; 33(42): World Health Organization. Recommended composition of influenza virus vaccines for use in the northern hemisphere influenza season. Available at: ndation.pdf. Accessed 9 March Wijnans L, Voordouw B. A review of the changes to the licensing of influenza vaccines in Europe. Influenza and other respiratory viruses 2016; 10(1):
5 Grohskopf LA, Sokolow LZ, Broder KR, et al. Prevention and Control of Seasonal Influenza with Vaccines. MMWR Recommendations and reports : Morbidity and mortality weekly report Recommendations and reports 2016; 65(5): World Health Organization. Vaccines against influenza WHO position paper - November Wkly Epidemiol Rec 2012; 87(47): Centers for Disease Control and Prevention. ACIP votes down use of LAIV for flu season. Available at: Accessed 7 March Global Alliance for Vaccines and Immunisation (GAVI). Final Vaccine Investment Strategy Analysis 2013: Maternal Influenza. Geneva, Switzerland: Global Alliance for Vaccines and Immunisation (GAVI), Immunization and Vaccine-related Implementation Research Advisory Committee (IVIR-AC): summary of conclusions and recommendations, 1-2 February 2017 meeting. Wkly Epidemiol Rec 2017; 92(15): Tudur Smith C, Hopkins C, Sydes MR, et al. How should individual participant data (IPD) from publicly funded clinical trials be shared? BMC medicine 2015; 13: von Elm E, Altman DG, Egger M, et al. The Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) statement: guidelines for reporting observational studies. J Clin Epidemiol 2008; 61(4):
ACIP Meeting June 22, 2016 Influenza Session: Key Points
Update: CDC s Advisory Committee on Immunization Practices (ACIP) voted in favor of an interim recommendation that live attenuated influenza vaccine (LAIV), also known as the nasal spray flu vaccine, should
More information2018 NAIIS Influenza Working Group Breakout Session
2018 NAIIS Influenza Working Group Breakout Session Amy Behrman, Amy Parker Fiebelkorn, Kelly McKenna NAIIS Influenza Working Group Co-Leads National Adult and Influenza Immunization Summit May 18, 2018
More informationExecutive Summary. Final version_29 Sept 2014 Page 1
Executive Summary Final version_29 Sept 2014 Page 1 WHO consultation on influenza vaccines for pregnant and lactating women: Clinical data requirements for product labelling 15 16 July 2014 Geneva, Switzerland
More informationWHO GLOBAL ACTION PLAN FOR INFLUENZA VACCINES
WHO GLOBAL ACTION PLAN FOR INFLUENZA VACCINES SURVEY QUESTIONNAIRE A.1. Introduction The Global Action Plan for Influenza Vaccines (GAP) was launched in 2006 as a ten year initiative to address the anticipated
More informationAccess to clinical trial information and the stockpiling of Tamiflu. Department of Health
MEMORANDUM FOR THE COMMITTEE OF PUBLIC ACCOUNTS HC 125 SESSION 2013-14 21 MAY 2013 Department of Health Access to clinical trial information and the stockpiling of Tamiflu 4 Summary Access to clinical
More informationThe human immunodeficiency virus/acquired immune
Vol. 7(4), pp. 44-48, May 2015 DOI: 10.5897/JAHR2014.0320 Article Number: 70F676253212 ISSN 2141-2359 Copyright 2015 Author(s) retain the copyright of this article http://www.academicjournals.org/jahr
More informationUses and misuses of the STROBE statement: bibliographic study
Uses and misuses of the STROBE statement: bibliographic study Bruno R. da Costa 1, Myriam Cevallos 1, 2, Douglas G. Altman 3, Anne W.S. Rutjes 1, Matthias Egger 1 1. Institute of Social & Preventive Medicine
More informationMaternal Influenza Immunization at WHO
Maternal Influenza Immunization at WHO Dr. Justin R. Ortiz Medical Officer Initiative for Vaccine Research GAP Partners Meeting Dubai, UAE 26 March 2014 WHO Position Paper Mother s Gift Trial GAVI Review
More informationRSV vaccine research and development: WHO technical roadmap
RSV vaccine research and development: WHO technical roadmap Johan Vekemans (MD, PhD) WHO Initiative for Vaccine Research Washington, 18 th December 2017 What is WHO s Initiative for Vaccine Research (IVR)
More informationEQUATOR Network: promises and results of reporting guidelines
EQUATOR Network: promises and results of reporting guidelines Doug Altman The EQUATOR Network Centre for Statistics in Medicine, Oxford, UK Key principles of research publications A published research
More informationResearch Integrity & Ethics. Rowena Lamb Cultures of Integrity Coordinator
Research Integrity & Ethics Rowena Lamb Cultures of Integrity Coordinator UCL Statement on Research Integrity Applies to all staff and students at UCL Sets out the standards all those involved with research
More informationThe Role and Importance of Clinical Trial Registries and Results Databases
The Role and Importance of Clinical Trial Registries and Results Databases March 2014 Rebecca J. Williams, Pharm.D., MPH Assistant Director, ClinicalTrials.gov National Library of Medicine, National Institutes
More informationCMS Issues New Draft Guidance on Coverage with Evidence Development Policy for National Coverage Determinations
December 6, 2012 CMS Issues New Draft Guidance on Coverage with Evidence Development Policy for National Coverage Determinations For more information, contact: Seth H. Lundy +1 202 626 2924 slundy@kslaw.com
More informationIdentifying barriers to influenza vaccination recommendation adherence in an academic outpatient primary care clinic setting
Volume 5 Number 3 Article 176 2014 Identifying barriers to influenza vaccination recommendation adherence in an academic outpatient primary care clinic setting Jenni Buu Shantel Mullin Carrie McAdam-Marx
More informationImproving reporting for observational studies: STROBE statement
Improving reporting for observational studies: STROBE statement Technical meeting on the reporting of human studies submitted for the scientific substantiation of health claims EFSA Parma 20 November 2013
More informationCONTAGIOUS COMMENTS Department of Epidemiology
VOLUME XXXIII NUMBER 4 September 2018 CONTAGIOUS COMMENTS Department of Epidemiology Influenza Vaccination Suchitra Rao, MBBS and Jason Child, PharmD New influenza vaccines have arrived. It is important
More informationSwine Flu. Media Briefing. 13 January 2011
Swine Flu Media Briefing 13 January 2011 Overview Systems for monitoring swine flu Pattern of flu in Northern Ireland Updated swine flu deaths Vaccination programme Systems for Monitoring Flu Special arrangements
More informationThe Inclusion of Seasonal Influenza Viruses and Genetic Sequence Data (GSD) in the Context of the Pandemic Influenza Preparedness (PIP) Framework
The Inclusion of Seasonal Influenza Viruses and Genetic Sequence Data (GSD) in the Context of the Pandemic Influenza Preparedness (PIP) Framework A position paper from the Directors of the GISRS WHO Collaborating
More informationWHO International Clinical Trials Registry Platform (ICTRP)
ECPC Brainstorming Meeting on Establishing A European Clinical Trials Registry, Milan, May 30, 2005 WHO International Clinical Trials Registry Platform (ICTRP) Tikki Pang Research Policy & Cooperation
More informationDeveloping a Target Product Profile for a Preventive HIV Vaccine
Developing a Target Product Profile for a Preventive HIV Vaccine Topics to be Covered Overview of TPPs What are they? What is the purpose and benefit of using a TPP? What is usually in a TPP? What are
More informationACIP Recommendations
ACIP Recommendations Lisa Grohskopf, MD, MPH Influenza Division National Center for Immunization and Respiratory Diseases Centers for Disease Control and Prevention National Influenza Vaccine Summit May
More informationPreventive Care and Screening: Influenza Immunization
e Title e Identifier ( Authoring Tool) Preventive Care and Screening: Influenza Immunization 147 e Version number 6.1.000 NQF Number 0041 GUID a244aa29-7d11-4616-888a-86e376bfcc6f ment Period Steward Developer
More informationUpdate on influenza maternal immunization. Joachim Hombach WHO Initiative for Vaccine Research
Update on influenza maternal immunization Joachim Hombach WHO Initiative for Vaccine Research Influenza Burden of Disease WHO global estimate: 3-5 million severe cases, 250 000 500 000 deaths
More informationWhat s New in Flu? An Update on Influenza Prevention and Treatment
What s New in Flu? An Update on Influenza Prevention and Treatment Kathryn M. Edwards MD Sarah H. Sell and Cornelius Vanderbilt Professor of Pediatrics Vanderbilt University Nashville, TN, USA Disclosures
More informationResponse to: Concept paper of 9 February 2011 submitted for public consultation by the European Commission on the
Response to: Concept paper of 9 February 2011 submitted for public consultation by the European Commission on the REVISION OF THE CLINICAL TRIALS DIRECTIVE 2001/20/EC Submitted by the European AIDS Treatment
More informationUPDATE ON IMMUNIZATION GUIDELINES AND PRACTICES
DISCLOSURES UPDATE ON IMMUNIZATION GUIDELINES AND PRACTICES Nothing to disclose Kylie Mueller, Pharm.D., BCPS Clinical Specialist, Infectious Diseases Spartanburg Regional Medical Center LEARNING OBJECTIVES
More informationTalkin Flu Mid-America Immunization Coalition August 18, William Atkinson, MD, MPH Immunization Action Coalition
Talkin Flu Mid-America Immunization Coalition August 18, 2016 William Atkinson, MD, MPH Immunization Action Coalition Disclosures William Atkinson has worked as a consultant to Merck and as a speaker for
More informationSeptember 14, All Medical Providers and Health Care Facilities. NYSDOH Bureau of Immunization
September 14, 2009 TO: FROM: All Medical Providers and Health Care Facilities NYSDOH Bureau of Immunization HEALTH ADVISORY: Novel H1N1 Influenza Vaccine Information Please distribute to the Infection
More informationPlatforms. Adolescent Immunization Update and the 16 Year Old Platform. Advisory Committee on Immunization Practices (ACIP)
Adolescent Immunization Update and the 16 Year Old Platform William Atkinson, MD, MPH Associate Director for Immunization Education Immunization Action Coalition Advisory Committee on Immunization Practices
More informationSurveillance of influenza in Northern Ireland
Surveillance of influenza in Northern Ireland 2011-2012 Summary: The influenza season started later than normal, clinical indices began to increase marginally in mid-february, much later than previous
More informationSee Important Reminder at the end of this policy for important regulatory and legal information.
Clinical Policy: (Xofluza) Reference Number: CP.PMN.185 Effective Date: 10.30.18 Last Review Date: 11.18 Line of Business: Commercial, Medicaid Revision Log See Important Reminder at the end of this policy
More informationStand on Guard for Thee
Stand on Guard for Thee Ethical Considerations in Preparedness Planning for Pandemic Influenza Alison Thompson, PhD University of Toronto Joint Centre for Bioethics Pandemic Influenza Working Group Members
More informationMeasles vaccine: a 27-year follow-up.
Measles vaccine: a 27-year follow-up. Item type Authors Article Ramsay, M E; Moffatt, D; O'Connor, M Citation Measles vaccine: a 27-year follow-up. 1994, 112 (2):409-12 Epidemiol. Infect. Journal Rights
More informationUpdate on Healthcare Personnel Influenza Vaccination
Update on Healthcare Personnel Influenza Vaccination Raymond A. St rikas, MD, MPH Immunization Services Division National Center for Immunization and Respiratory Diseases October 23, 2012 National Center
More informationDisparities in influenza vaccination coverage rates in health care workers and the ways to overcome the barriers
Disparities in influenza vaccination coverage rates in health care workers and the ways to overcome the barriers Dr. Patricia R. Blank Barcelona - November 15, 2012 The Menu 1. Situation in Europe Recommendations
More informationPIP Framework Information Session 10 April 2018
Pandemic Influenza Preparedness Framework Sharing of influenza viruses & access to vaccines and other benefits PIP Framework Information Session 10 April 2018 PIP Framework Information Session Purpose:
More informationFrom Vaccine Development to Policy: A Brief Review of WHO Vaccine-Related Activities and Advisory Processes (2017)
1. Introduction From Vaccine Development to Policy: A Brief Review of WHO Vaccine-Related Activities and Advisory Processes (2017) To help achieve the implementation of the Global Vaccine Action Plan (GVAP),
More informationNovember 13, 2009 Licensure, Evaluation, and Adverse Event Monitoring of the 2009 H1N1 Influenza Vaccine By Matthew Watson and Jennifer Nuzzo
www.upmc-biosecurity.org www.upmc-cbn.org November 13, 2009 Licensure, Evaluation, and Adverse Event Monitoring of the 2009 H1N1 Influenza Vaccine By Matthew Watson and Jennifer Nuzzo In response to the
More informationUpdate on A(H1N1) pandemic and seasonal vaccine availability. July 7, 2009
Update on A(H1N1) pandemic and seasonal vaccine availability July 7, 2009 Presentation objectives and approach Presentation Objectives Review production status for 2009-2010 Northern Hemisphere vaccine
More informationSentinel Initiative Public Workshop. The Brookings Institution Marriott at Metro Center Washington, DC Tuesday, January 14, 2014
Sentinel Initiative Public Workshop The Brookings Institution Marriott at Metro Center Washington, DC Tuesday, January 14, 2014 State of CBER s Mini-Sentinel Activities Michael Nguyen, MD Division of Epidemiology
More informationWORLD MEDICAL ASSOCIATION DECLARATION OF HELSINKI. Ethical Principles for Biomedical Research Involving Human Beings
WORLD MEDICAL ASSOCIATION DECLARATION OF HELSINKI Ethical Principles for Biomedical Research Involving Human Beings WMA Review of the Declaration of Helsinki Consultation Response of the PHG Foundation
More informationACIP Recommendations for Pneumococcal 13-valent Conjugate and 23-valent Polysaccharide Vaccine Use among Adults
ACIP Recommendations for Pneumococcal 13-valent Conjugate and 23-valent Polysaccharide Vaccine Use among Adults National Center for Immunization & Respiratory Diseases Respiratory Diseases Branch ACIP
More informationGavi, the Vaccine Alliance - Health System and Immunisation Strengthening (HSIS) Support Framework
Gavi, the Vaccine Alliance - Health System and Immunisation Strengthening (HSIS) Support Framework I. Purpose This Framework sets out the principles and several essential requirements for Gavi s Health
More informationUpdating the Malaria Vaccine Technology Roadmap
Updating the Malaria Vaccine Technology Roadmap Vasee Moorthy MRCP PhD MPAC 14 March 2013 Purpose of this MPAC session MPAC to be updated on the strategic R&D framework for malaria vaccines, including
More informationVaccinology Overview. Complexity of the Vaccine Approval Process Including Lessons Learned
Vaccinology Overview Complexity of the Vaccine Approval Process Including Lessons Learned Larry K. Pickering, MD, FAAP, FIDSA, FPIDS August 18, 2018 Faculty Disclosure Information In the past 12 months,
More informationSystematic Reviews. Simon Gates 8 March 2007
Systematic Reviews Simon Gates 8 March 2007 Contents Reviewing of research Why we need reviews Traditional narrative reviews Systematic reviews Components of systematic reviews Conclusions Key reference
More informationInfluenza Vaccines: The Good, The Bad, The Controversies
Influenza Vaccines: The Good, The Bad, The Controversies Janet A. Englund, M.D. Dept. Of Pediatrics, Seattle Children s Hospital, University of Washington Fred Hutchinson Cancer Research Center Sept. 25,
More informationTable S1- PRISMA 2009 Checklist
Table S1- PRISMA 2009 Checklist Section/topic TITLE # Checklist item Title 1 Identify the report as a systematic review, meta-analysis, or both. 1 ABSTRACT Structured summary 2 Provide a structured summary
More informationGuideline on influenza vaccines submission and procedural requirements
1 2 3 October 2014 EMA/56793/2014 Human Medicines Research and Development Support 4 5 6 Guideline on influenza vaccines submission and procedural requirements Regulatory and procedural requirements module
More informationInfluenza: A recap of the season
Influenza: A recap of the 2012 2013 season March 22, 2013 Debra Blog MD, MPH Director Division of Epidemiology What are we going to talk about The 2012 13 Influenza Vaccine Influenza Activity and Surveillance
More informationInfluenza Update. Lisa Grohskopf, MD, MPH Influenza Division, CDC. NAICP Call 6 October 2015
Influenza Update Lisa Grohskopf, MD, MPH Influenza Division, CDC NAICP Call 6 October 2015 National Center for Immunization and Respiratory Diseases Influenza Division Overview Surveillance update ACIP
More informationEstimates of Influenza Vaccination Coverage among Adults United States, Flu Season
Estimates of Influenza Vaccination Coverage among Adults United States, 2017 18 Flu Season On This Page Summary Methods Results Discussion Figure 1 Figure 2 Figure 3 Figure 4 Table 1 Additional Estimates
More informationWHO INFLUENZA VACCINE RECOMMENDATION
WHO INFLUENZA VACCINE RECOMMENDATION Strategic Advisory Group of Experts (SAGE) on Immunization SAGE Working Group on Influenza Vaccine and Immunization 1 Evidence Evaluation: Conceptual Matrix Target
More informationMA Adult Immunization Coaltion Flu Update September 28, 2016
MA Adult Immunization Coaltion Flu Update September 28, 2016 Susan M. Lett, MD, MPH Medical Director, Immunization Program Division of Epidemiology and Immunization Massachusetts Department of Public Health
More informationPreparing a US FDA Medical Device 510(K) Submission
Preparing a US FDA Medical Device 510(K) Submission If you want to introduce your medical device to the US market, you need to obtain clearance from the FDA. This clearance is obtained from the FDA via
More informationChallenges and solutions in making evidence-based national vaccination policies and recommendations
Challenges and solutions in making evidence-based national vaccination policies and recommendations Philippe Duclos, WHO 15th ADVAC, Les Pensières, Veyrier du Lac, May 19, 2014 Developing evidence-based
More informationSubmission of comments on 'Policy 0070 on publication and access to clinical-trial data'
EMA/240810/2013 Submission of comments on 'Policy 0070 on publication and access to clinical-trial data' s from: Name and affiliation Institute for Quality and Efficiency in Health Care (IQWiG) Im Mediapark
More informationUpdate ACIP Influenza Vaccination Recommendations for
Update ACIP Influenza Vaccination Recommendations for 2014-15 Lisa Grohskopf, MD, MPH Influenza Division, CDC IAC Webinar 11 September 2014 National Center for Immunization and Respiratory Diseases Influenza
More informationOverall presentation of IVR Strategy
Annex 3 Overall presentation of IVR Strategy Presentation to the IVR Advisory committee (IVAC) April 2007 Outline Why does WHO invest in Research & Development? What is the Initiative for Vaccine Research
More informationOverview and Comparisons of Risk of Bias and Strength of Evidence Assessment Tools: Opportunities and Challenges of Application in Developing DRIs
Workshop on Guiding Principles for the Inclusion of Chronic Diseases Endpoints in Future Dietary Reference Intakes (DRIs) Overview and Comparisons of Risk of Bias and Strength of Evidence Assessment Tools:
More informationInfluenza Weekly Surveillance Bulletin
Influenza Weekly Surveillance Bulletin Northern Ireland, Week 7 (15 February 216 21 February 216) Summary In Northern Ireland, as of week 7 216, the 215/16 influenza season has seen low community influenza
More informationA (Constructive/Provocative) Critique of the ICH E9 Addendum
A (Constructive/Provocative) Critique of the ICH E9 Addendum Daniel Scharfstein Johns Hopkins University dscharf@jhu.edu April 18, 2018 1 / 28 Disclosures Regularly consult with pharmaceutical and device
More informationDiscovery and validation of novel. Webinar IMI2 - Call 9 Joint influenza vaccine effectiveness studies
Discovery and validation of novel Webinar IMI2 - Call 9 Joint influenza vaccine effectiveness studies Dr. Angela Wittelsberger, IMI IMI webinar 29.04.2016 Today s webinar Will cover all aspects of the
More informationSurveillance of Influenza in Northern Ireland
Surveillance of Influenza in Northern Ireland 2016 2017 Contents Summary... 1 Introduction... 3 Enhanced influenza surveillance systems... 3 In-hours Sentinel GP Practice surveillance... 3 GP Out-of-Hours
More information1. The World Bank-GAVI Partnership and the Purpose of the Review
1. The World Bank-GAVI Partnership and the Purpose of the Review 1.1 The new World Bank Group strategy makes a strong case for an expanded World Bank Group role in global and regional dialogue and collective
More informationPlanning for the Novel H1N1 Influenza Vaccination Campaign
Planning for the Novel H1N1 Influenza Vaccination Campaign Debra Blog, MD, MPH, Director Bureau of Immunization New York State Department of Health October 7, 2009 1 Influenza Prevention Influenza vaccination
More informationWHO VACCINE SUPPLY & QUALITY SUPPORT FOR NATIONAL IMMUNIZATION PROGRAMMES
WHO VACCINE SUPPLY & QUALITY SUPPORT FOR NATIONAL IMMUNIZATION PROGRAMMES Immunization and vaccine development in the last decade Since the Millennium Summit in 2000, immunization substantial international
More informationSeasonal Influenza Report
Key findings for the 2017 2018 flu season October 1 st, 2017 (CDC Disease Week 40) marked the beginning of the 2017 2018 influenza season. Influenza activity is increasing in California. As of November
More informationDissemination experiences from CONSORT and other reporting guidelines
Dissemination experiences from CONSORT and other reporting guidelines Doug Altman Centre for Statistics in Medicine, Oxford EQUATOR Network [Altman and Goodman, JAMA 1994] 2 Passive
More informationPandemic Influenza Preparedness and Response
24 th Meeting of Ministers of Health Dhaka, Bangladesh, 20-21 August 2006 SEA/HMM/Meet.24/4(b) 10 July 2006 Pandemic Influenza Preparedness and Response Regional situation: Human cases and outbreaks of
More informationInfluenza Weekly Surveillance Bulletin
Influenza Weekly Surveillance Bulletin Northern Ireland, Week 6 (8 February 216 14 February 216) Summary In Northern Ireland, as of week 6 215, the 215/16 influenza season has seen low community influenza
More informationDownloaded from:
Hemingway, H; Croft, P; Perel, P; Hayden, JA; Abrams, K; Timmis, A; Briggs, A; Udumyan, R; Moons, KG; Steyerberg, EW; Roberts, I; Schroter, S; Altman, DG; Riley, RD; PROGRESS Group (2013) Prognosis research
More informationProstate Cancer Priority Setting Partnership. PROTOCOL June 2009
Prostate Cancer Priority Setting Partnership PROTOCOL June 2009 Purpose The purpose of this protocol is to set out the aims, objectives and commitments of the Prostate Cancer Priority Setting Partnership
More informationUpdated Questions and Answers related to the dengue vaccine Dengvaxia and its use
WHO Secretariat Updated Questions and Answers related to the dengue vaccine Dengvaxia and its use Published 22 December 2017 This document takes into account new and unpublished data that were communicated
More informationImproving Flu Vaccination Rates at the Institute for Family Health at 17th Street the Old-Fashioned Way
Improving Flu Vaccination Rates at the Institute for Family Health at 17th Street the Old-Fashioned Way Anup Bhandiwad, MD Andrew Chen, MD Rebecca Giusti, MD Ines Teuma, MD Background Since 2010 there
More informationSeasonal influenza vaccination programme country profile: United Kingdom Northern Ireland
Seasonal influenza vaccination programme country profile: United Kingdom Northern Ireland 2012 13 Season Background information Influenza immunisation policy and general facts about the United Kingdom
More information2016/2017 Influenza Season
2016/2017 Influenza Season 1 In healthy adults symptoms of flu can range from classic influenza to mild illness asymptomatic infection 10/9/2013 2 Symptoms Cold Classic Flu Fever Rare Very common Headache
More informationInfluenza A(H1N1) aka Swine Flu. IAP ACVIP statement on ongoing outbreak of H1N1 in India. Situational analysis: Historical perspectives
Influenza A(H1N1) aka Swine Flu IAP ACVIP statement on ongoing outbreak of H1N1 in India Situational analysis: Historical perspectives H1N1 pandemic in 2009-10: The pandemic of A (H1N1) was first reported
More informationGAVI S VACCINE INVESTMENT STRATEGY
GAVI S VACCINE INVESTMENT STRATEGY Judith Kallenberg, Head of Policy PDVAC 22 June 2017, Geneva Reach every child www.gavi.org Gavi finances vaccines and immunisation through three routes ($9 Billion in
More informationSystematic reviews and meta-analyses of observational studies (MOOSE): Checklist.
Systematic reviews and meta-analyses of observational studies (MOOSE): Checklist. MOOSE Checklist Infliximab reduces hospitalizations and surgery interventions in patients with inflammatory bowel disease:
More informationMeasuring brand-specific influenza vaccine effectiveness in EU/EEA
25.5.18 Call for tenders 2018/2019 influenza season Measuring brand-specific influenza vaccine effectiveness in EU/EEA Tender Specifications Acknowledgement. The DRIVE project has received funding from
More informationPartnership Contribution Standard Operating Procedures June 2015
Partnership Contribution Standard Operating Procedures June 2015 This document replaces the version dated May 2013 In May 2011, the Sixty- fourth World Health Assembly adopted the Pandemic Influenza Preparedness
More informationAdvancing RSV maternal immunization: A gap analysis brief An analysis to identify needs for vaccine decision-making and introduction
Advancing RSV maternal immunization: A gap analysis brief An analysis to identify needs for vaccine decision-making and introduction Despite significant advances in child survival, deaths in the earliest
More information2008 Public Status Report on the Implementation of the European Risk Management Strategy. Executive Summary
European Medicines Agency London, 17 March 2009 Doc. Ref. EMEA/43556/2009 2008 Status Report on the Implementation of the European Risk Management Strategy Executive Summary The European Risk Management
More informationRandomized Controlled Trial
Randomized Controlled Trial Training Course in Sexual and Reproductive Health Research Geneva 2016 Dr Khalifa Elmusharaf MBBS, PgDip, FRSPH, PHD Senior Lecturer in Public Health Graduate Entry Medical
More informationReport to the. GAVI Alliance Board June 2013
Report to the GAVI Alliance Board 11-12 June 2013 Subject: Report of: Authored by: Risk Management Update Helen Evans, Deputy CEO Ciara Goldstein, Analyst, Performance Management and Adrien de Chaisemartin,
More informationCenter for Biologics Evaluation and Research
Center for Biologics Evaluation and Research Current Activities Future Directions Washington, DC January 25, 2010 Karen Midthun, MD Acting Director, CBER CBER Our Mission To ensure the safety, purity,
More informationAlberta Health. Seasonal Influenza in Alberta. 2016/2017 Season. Analytics and Performance Reporting Branch
Alberta Health Seasonal Influenza in Alberta 2016/2017 Season Analytics and Performance Reporting Branch September 2017 For more information contact: Analytics and Performance Reporting Branch Health Standards,
More informationAccuracy, Completeness, and Transparency: lessons from Tamiflu experience
Accuracy, Completeness, and Transparency: lessons from Tamiflu experience Peter Doshi, PhD (pnd@jhu.edu) Postdoctoral fellow in Comparative Effectiveness Research Johns Hopkins University School of Medicine
More informationJuly 7, Dockets Management Branch (HFA-305) Food and Drug Administration 5630 Fishers Lane, Rm Rockville, MD 20852
July 7, 2012 Dockets Management Branch (HFA-305) Food and Drug Administration 5630 Fishers Lane, Rm. 1061 Rockville, MD 20852 Re: Docket No. FDA 2012-N-0408: Risk Evaluation and Mitigation Strategy Assessments:
More information9/23/2015. Introduction & Background. Determinants of Seasonal Flu Vaccine Hesitancy Among University Students in the US
Introduction & Background Determinants of Seasonal Flu Vaccine Hesitancy Among University Students in the US ML MPH, CG MD, EM PhD, SK PhD, and TG PhD, MPH Presenter: Maxine Langenfeld Epidemiology Department,
More informationSeasonal Influenza Report
Key findings for the 2017 2018 flu season Seasonal Influenza Report 2017 2018 Influenza activity remains elevated throughout California. As of 2018 week 9 (February 25 March 3, 2018), the statewide geographic
More informationPractice Direction Standard of Practice # 5: Administration of Drugs including Vaccines
Practice Direction Standard of Practice # 5: Administration of Drugs including Vaccines 1.0 Scope and Objective: 1.1 Expected Outcome This document is a practice direction by Council concerning the implementation
More informationSANOFI PASTEUR, LEADING PROVIDER OF SEASONAL INFLUENZA VACCINES
FACT SHEET SANOFI PASTEUR, LEADING PROVIDER OF SEASONAL INFLUENZA VACCINES WORLD S LEADING INFLUENZA VACCINE MANUFACTURER Annual production capacity of Sanofi Pasteur seasonal influenza vaccines have doubled
More informationGavi Alliance Conflict of Interest Policy Version 2.0
Version 2.0 DOCUMENT ADMINISTRATION VERSION NUMBER 1.0 APPROVAL PROCESS DATE Reviewed by: Gavi Governance Committee 15 April 2009 Approved by: Gavi Alliance Board 2.0 Prepared by: Legal and Governance
More informationInfluenza Weekly Surveillance Bulletin
Influenza ly Surveillance Bulletin Northern Ireland, (11-17 December ) Summary All indicators of influenza virus activity have increased. GP consultation rates for combined flu/ FLI increased from 28.1/,
More informationIssue No.1, December 2010 From the WHO Regional Office for Europe, WHO/EURO -
Issue No.1, December 2010 From the WHO Regional Office for Europe, WHO/EURO - http://www.euro.who.int/ Flu Focus is an e-magazine published by the WHO Regional Office for Europe that covers recent developments,
More informationTamiflu. Tamiflu (oseltamivir) Description
Federal Employee Program 1310 G Street, N.W. Washington, D.C. 20005 202.942.1000 Fax 202.942.1125 5.01.19 Subject: Tamiflu Page: 1 of 5 Last Review Date: March 18, 2016 Tamiflu Description Tamiflu (oseltamivir)
More informationInfluenza Weekly Surveillance Bulletin
Influenza ly Surveillance Bulletin Northern Ireland, ( 1 January ) Summary GP consultation rates for combined flu/ FLI decreased from 1./, population (updated) in week to./, in week (4% decrease). o flu/fli
More informationInfluenza vaccine Revisiting Old and Addressing Current Issues. Dr. Leilani T. Sanchez, DPPS, DPIDSP Manila, 18 February 2016
Influenza vaccine Revisiting Old and Addressing Current Issues Dr. Leilani T. Sanchez, DPPS, DPIDSP Manila, 18 February 2016 QIV QIV 2 Influenza Leilani Sanchez, MD 18 Feb 2016 PIDSP Annual Convention
More information